Evaxion Biotech A/S (EVAX)
Evaxion Biotech A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Horsholm, ND, DK. The stock last traded at $3.34, up 2.45% on the session, giving a market capitalisation of $21.1M. On trailing twelve-month figures it carries a trailing P/E of -0.54, a net margin of -115.5%. Its beta of 0.27 implies it has historically moved less than the broad market.
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Evaxion Biotech A/S is most often compared with the following Healthcare names: